Business Wire

RoboSense Launched E1, A High-Performance Flash Solid-State LiDAR and Debuted A Smart Manufacturing System with An Annual Output of A Million Units

8.11.2022 15:28:00 EET | Business Wire | Press release

Share

RoboSense, a world-leading provider of Smart LiDAR Sensor Systems, held a new product launch and Tech Day event. During the conference, RoboSense officially launched RS-LiDAR-E1 (E1), a flash solid-state LiDAR that sees 360° based on its in-house, custom developed chips and flash technology platform. Also debuted was the only China National Accreditation Service (CNAS) recognized on-board LiDAR lab of the industry to date, and held the unveiling ceremony of the smart manufacturing joint venture, Luxsense, jointly with Luxshare-ICT, a domestic leading electronics manufacturer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221108005666/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

RoboSense Tech Day Launched E1, A High-Performance Flash Solid-State LiDAR and Debuted A Smart Manufacturing System with An Annual Output of A Million Units (Graphic: Business Wire)

RoboSense launched E1, the first automotive-grade flash solid-state LiDAR. It serves as a new product platform featuring area array transceiver technology with application-specific developed chips as the core. E1 is designed for large-scale series production with a simple bill of materials including no moving parts, and excels in all the three aspects of detection performance, cost efficiency and automotive-grade safety and reliability of LiDARs. As a key piece to realizing the core functions of autonomous driving, E1 will assist partners to further bridge the gap in smart driving perception and improve the all-scenario perception capability of automated and autonomous vehicles.

4 core features of E1

  • Horizontal FOV of 120°, which ensures 360° coverage area without blind zone using minimum sensors.
  • Vertical FOV is designed to be 90°, to allow the perception area to cover both blind zones on the ground and lateral vision.
  • Ultra-high frame rates of over 25Hz, capturing target objects’ motion states and predicting their moves faster.
  • Detection range of 30m @10%, which enables better perception planning control.

E1 uses RoboSense’s first in-house, custom chips for flash solid-state LiDAR platform and its first 2D electronic scanning technology. With highly integrated chips that incorporate the three core components of transmission, reception, and processing, E1 greatly streamlines the circuit design and production processes, creating the performance and cost advantages necessary for the durability and reliability requirements of blind spot LiDARs in the automotive market.

To ensure product performance and rapidly improve production capacity, RoboSense launched the first and only CNAS certified LiDAR lab to analyze LiDAR and their components and developed a complementary smart manufacturing system to produce this high-tech, precision sensor.

During the event, leaders of RoboSense and Luxshare jointly held the unveiling ceremony of Luxsense. Investment in the first phase of RoboSense smart manufacturing system exceeded 1 billion RMB cumulatively; the plant area exceeds 55,000 square meters including nearly 20 automated production lines built with highly intelligent production software to achieve a top-level production efficiency of “a LiDAR every 12 seconds” and guarantees capacity by connecting our Shenzhen, Dongguan and Guangzhou plants.

Additionally, RoboSense announced a new strategic financing round which attracted top industry investors. In particular, industry investors in this new financing round include car companies with self-owned brands, emerging automakers, top luxury supercar brands, leading commercial vehicle companies, supply chain pioneers and the tier 1 institutions. Greatly empowered by capital investments from the industry, RoboSense gained unprecedented momentum and sustainability.

About RoboSense

RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Grace Ye
media@robosense.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye